MedTrace Logo

Sitagliptin Versus Sulphonylurea in Type 2 Diabetes During Ramadan

NCT00766441 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2010-01-12

No results posted yet for this study

Summary

This study will assess if Sitagliptin addition to metformin or glitazone is better than current sulphonylurea based treatments during Ramadan. The rationale is that Sitagliptin offers metabolic advantages primarily with the low incidence of hypoglycemia over current sulphonylurea based treatments.

Conditions

Interventions

DRUG

Sitagliptin

tablet, 100mg, once daily, 4 weeks

DRUG

sulphonylurea

sulphonylurea, variable, od or bd, during ramadan

Sponsors & Collaborators

  • University of Manchester

    lead OTHER

Principal Investigators

  • Rayaz A Malik, MBChB, PhD · University of Manchester

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
78 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2009-10-31
Completion
2009-10-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00766441 on ClinicalTrials.gov